Indicatum

Investera med insikt - Data visar vägen!

Bevaka (0)

Calliditas Therapeutics

Lista

Mid Cap

Sektor

Health Care

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company’s lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.


Ranks


Kursgraf

Länk till dynamisk (zoombar) graf för större skärmar


Nuvarande och kommande formation


MA Rank

Free stock photo of 4k wallpaper, bridge, daylight
Photo by Markus Spiske on Pexels

Välkommen till Indicatum!

Vi bygger vår nya plattform och kan tyvärr inte ta emot nyregistreringar just nu, men registrera din e-postadress nedan så får du en notis när vi lanserar tjänsten.

Vi ser fram emot att höra från dig!

Vi spammar inte!
Din email kommer endast att användas för att meddela dig när plattformen lanseras

Rulla till toppen